Tesamorelin is a synthetic analog of endogenous Growth Hormone Releasing Hormone
(GHRH), comprising the full 44 amino acid sequence of human GHRH with a
trans-3-hexenoic acid modification that enhances stability and bioavailability.
Compound Details (per vial):
— Tesamorelin: 10mg
— Form: Lyophilized powder
— Purity: ≥98%
Tesamorelin is the only GHRH analog with FDA approval (granted under the brand
name Egrifta for HIV-associated lipodystrophy), making it one of the most
clinically validated peptides in the GH secretagogue class. Phase III randomized
controlled trials documented a 15–18% reduction in visceral adipose tissue (VAT)
and sustained IGF-1 elevation over the treatment period. Unlike exogenous GH
administration, Tesamorelin preserves the natural pulsatile pattern of GH release,
maintaining the body’s endocrine feedback mechanisms. Researchers studying visceral
fat metabolism, GH deficiency models, IGF-1 axis regulation, and body composition
use Tesamorelin as the reference GHRH analog due to its unmatched clinical data
depth. It stacks synergistically with Ipamorelin in dual-pathway GH research models.
Supplied lyophilized in a sterile sealed vial. Third-party tested for identity
and purity prior to release. Not for human consumption. For research use only.
Reviews
There are no reviews yet.